Skip to main content

Table 1 Baseline characteristics of randomized clinical trials using SLT

From: Where does selective laser trabeculoplasty stand now? A review

Author, year Design, location Type of glaucoma # eyes after SLT Treatment in control arm Mean follow-up (months) Mean age (years) SLT group baseline IOP (mmHg) Control group baseline IOP (mmHg) Characteristics SLT (extent, number spots, power)
Lai, 2004 [22] SC, China POAG, OHT 29 medication (not specified) 60 51.9 ± 14.7 26.8 ± 5.6 26.2 ± 4.2 360°, 100, 1.0 ± 0.1 mJ
Nagar, 2005 [23] MC, UK POAG, OHT, PEX, PDS 128 medication (lat) 10.3 63 NA NA 90° (25–30 spots),
180° (48–53 spots),
360° (93–102 spots),
0.8-1.7 mJ
Nagar, 2009 [24] SC, UK POAG, OHT 20 medication (lat) 4–6 66.4 26.1 ± 4.0 22.8 ± 4.5 360°, 100 ± 5, 0.8–1.4 mJ
Katz, 2012 [21] MC, USA POAG, OHT 67 medication (prost) 6–12 NA 25.0 ± 2.2 (4–6 mth group), 24.5 ± 2.1 (9–12 mth group) 24.5 ± 2.2 (4–6 mth group), 24.7 ± 2.4 (9–12 mth group) 360°, 100, 0.8–1.2 mJ
Bovell, 2011 [26] SC, Canada POAG, PEX, PDS, mix mech, others 89 ALT 60 69.7 ± 10.52 23.8 ± 4.9 23.48 ± 4.21 180°, 50, 0.47–1.5 mJ
Liu, 2012 [27] SC, Canada POAG, OHT, PEX, PDS, NTG, juv OAG, mix mech 20 ALT 37 48.7 ± 9.4 19.1 ± 4.5 21.9 ± 4.4 180°, 45–55, 0.7–0.8 mJ
Rosenfeld, 2012 [28] SC, Israel POAG, OHT, PEX, PDS 22 ALT 12 71.95 25.36 ± 1.83 25.11 ± 2.16 180°, 50–70, 0.8–1.2 mJ
Kent, 2013 [29] MC, Canada PEX 37 ALT 6 72.9 ± 9.86 23.1 ± 4.22 25.2 ± 4.87 180°, 53 ± 3.75, 0.6 mJ
  1. Abbreviations: SC = single centre; MC = multicentre; NA = not available; POAG = primary open angle glaucoma; OHT = ocular hypertension; PDS = pigment dispersion syndrome; PEX = pseudoexfoliation syndrome; NTG = normal tension glaucoma; juv = juvenile glaucoma; mix mech = mixed mechanism glaucoma; lat = latanoprost; prost = prostaglandin analog